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Background: Plasmodium falciparum histidine-rich protein PFHRP2 measurement is used widely for diagnosis, and
more recently for severity assessment in falciparum malaria. The Pfhrp2 gene is highly polymorphic, with deletion of
the entire gene reported in both laboratory and field isolates. These issues potentially confound the interpretation
of PFHRP2 measurements.
Methods: Studies designed to detect deletion of Pfhrp2 and its paralog Pfhrp3 were undertaken with samples from
patients in seven countries contributing to the largest hospital-based severe malaria trial (AQUAMAT). The
quantitative relationship between sequence polymorphism and PFHRP2 plasma concentration was examined in
samples from selected sites in Mozambique and Tanzania.
Results: There was no evidence for deletion of either Pfhrp2 or Pfhrp3 in the 77 samples with lowest PFHRP2
plasma concentrations across the seven countries. Pfhrp2 sequence diversity was very high with no haplotypes
shared among 66 samples sequenced. There was no correlation between Pfhrp2 sequence length or repeat type
and PFHRP2 plasma concentration.
Conclusions: These findings indicate that sequence polymorphism is not a significant cause of variation in PFHRP2
concentration in plasma samples from African children. This justifies the further development of plasma PFHRP2
concentration as a method for assessing African children who may have severe falciparum malaria. The data also
add to the existing evidence base supporting the use of rapid diagnostic tests based on PFHRP2 detection.
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The Plasmodium falciparum histidine-rich proteins
PFHRP2 and PFHRP3 [1] are soluble proteins contain-
ing highly antigenic tandem repeat sequences [2] and
are produced in large quantities during the asexual
blood stage of the P. falciparum lifecycle [3] where* Correspondence: noi@tropmedres.ac; charlie@tropmedres.ac
2Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical
Medicine, Mahidol University, Bangkok, Thailand
16Department of Molecular Tropical Medicine and Genetics, Faculty of
Tropical Medicine, Mahidol University, Bangkok, Thailand
Full list of author information is available at the end of the article
© 2012 Ramutton et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortheir concentration represents a dynamic equilibrium
[4]. Orthologs are not found in other species of
human malaria [5]. Antibody detection of PFHRP2
(which also picks up PFHRP3) is, therefore, a sensitive
method for the rapid diagnosis of P. falciparum malaria
using whole blood [6], as well as an in vitro drug sensitiv-
ity readout that has found increasing use in recent years
[7]. PFHRP2 is also released into plasma, where its con-
centration reflects the extent of current and previous
cycle parasite sequestration, a process considered critical
to the pathology of severe malaria [8].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Selection of samples examined for possible
Pfhrp2 and Pfhrp3 deletion
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teins more than two decades ago [1,9], their physio-
logical role in the lifecycle of P. falciparum has been
subject to a number of lines of investigation, with the
focus of most attention on haem polymerization [10]. A
degree of redundancy exists with parasites lacking one
or both of these proteins still able to propagate in asex-
ual stage culture and complete the entire parasite life
cycle [11-13]. Nevertheless, classical falciparum genetic
crosses in which one parent had a deletion of Pfhrp3
demonstrated complete [14] or partial [15] bias towards
Pfhrp3 inheritance (although the cross-over interval was
not fine enough to attribute enhanced fitness specifically
to Pfhrp3 as opposed to nearby genes). Perhaps surpris-
ingly, Pfhrp2 did not show inheritance bias in the HB3 x
Dd2 cross [15]; low-level transcription in the HB3 parent
[16] could potentially explain this in part or in whole.
In contrast to these studies on cultured isolates, prior
to 2010 no field isolates had been reported which lacked
either Pfhrp2 or Pfhrp3. However, relatively recent evidence
of significant numbers of parasites with deletion of one or
both genes has emerged in the Peruvian Amazon [17,18],
generating concerns over the reliability of PFHRP2-based
rapid diagnostic tests (RDTs) in this region. There has been
little evidence that deletion of either gene occurs to a
significant degree in Africa. This may reflect both the
true rarity of the event (given the predicted deleterious
effect on fitness), along with the higher multiplicities of
infection found in high transmission settings. It is there-
fore concerning that isolates from Mali lacking Pfhrp2
have now been described [19].
Both Pfhrp2 and Pfhrp3 also exhibit extensive insertion-
deletion polymorphism, and the potential for this to reduce
the accuracy of RDTs has been examined at national [20]
and global scales [21,22]. However, whether sequence vari-
ation is an important confounder in the assessment of
plasma concentration, and hence disease severity, has not
been studied. This study examined the relationship be-
tween Pfhrp2 sequence and plasma PFHRP2 concentration
in samples derived from a large group of African children
treated for severe malaria in the AQUAMAT trial [23].Country Site Available samples Samples tested (%)
DRC Kinshasa 420 6 (1.43)
The Gambia Banjul 60 2 (3.33)
Kenya Kilifi 378 12 (3.17)
Mozambique Beira 659 19 (2.88)
Rwanda Kigali 170 10 (5.88)
Nyanza 111 5 (4.50)
Tanzania Korogwe 534 3 (0.56)
Teule 901 15 (1.66)
Uganda Mbarare 593 5 (0.84)
Total 3826 77 (1.98)Methods
A PCR-based approach was used to answer a number of
related questions. First, Pfhrp2 deletions were sought in
parasites from patients admitted with a diagnosis of se-
vere malaria but who had very low or undetectable
plasma PFHRP2 levels by ELISA. Deletions in Pfhrp3
were also checked since by cross-reacting with PFHRP2,
the less abundant PFHRP3 allows RDTs to retain some
sensitivity even when Pfhrp2 deletions are present. Fi-
nally, the relationship between Pfhrp2 exon 2 length and
repeat structure and plasma concentration was explored.Samples
Samples were obtained from children enrolled in the
AQUAMAT trial, a large multinational trial comparing
quinine and artesunate for the treatment of severe mal-
aria in African children undertaken between October
2005 and July 2010 and described in detail elsewhere
[23]. Children were included if they showed signs of
severe malaria (defined by clinical criteria) and had a
positive P. falciparum lactate dehydrogenase RDT.
Patients were excluded if treated parenterally for more
than 24 hours before admission. Patients were rando-
mized to treatment with either parenteral artesunate or
quinine. Baseline blood samples included a peripheral
blood slide. Slide reading was performed by microsco-
pists at the Mahidol-Oxford Tropical Medicine Research
Unit and parasitaemia/μl was calculated from thin film
(count/1,000 RBCx125.6xHct) or thick film (count/200
WBCx40). Dried whole blood spots were used for mo-
lecular studies. EDTA blood for plasma PFHRP2 meas-
urement was received from nine of the 11 AQUAMAT
research sites in seven countries (Table 1).
DNA samples from established P. falciparum lines
(K1, Dd2, 3d7) were provided by MR4 and used to con-
trol Pfhrp2 and Pfhrp3 PCR results. A number of sam-
ples from within Asia were also tested to validate
methodology, confirming the finding [22] that Pfhrp2
exon 2 sequences from African samples are longer than
those from Cambodia, as they have substantially more
type 7 repeats. To reduce the potential confounding ef-
fect of differing clinical characteristics in patients
recruited in different sites, the relationship between
Pfhrp2 sequence and plasma concentration was focused
on sample sets from Mozambique and Tanzania (Teule).
Appropriate ethical approvals were granted by the Ox-
ford Tropical Research Ethics Committee, the Ethics
Committee of the Faculty of Tropical Medicine, Mahidol
University and the individual study site countries’ ethical
review boards.
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Parasite DNA from dried blood spots was extracted via
the QIAmp DNA Mini kit using the standard protocol
and stored at −20°C until use. For both Pfhrp2 and Pfhrp3,
a semi-nested PCR approach was used involving identical
primers and conditions to those already described by
Baker et al. [21]. These primers anneal to the conserved
end regions of exon 2 of Pfhrp2 and Pfhrp3, with the
intervening sequence encompassing the variable histidine-
rich repeats of these genes. To confirm P. falciparum
infection in Pfhrp2-negative samples or those with very
weak bands, a fully nested PCR Plasmodium species de-
tection approach was employed using specific oligo-
nucleotide primers to amplify a segment of ssrRNA
using published primers and conditions [24]. For Pfhrp2
sequencing, amplified DNA products were purified
using the Favorgen Gel/PCR purification kit according
to the manufacturer’s instructions. DNA concentrations
were estimated by agarose gel electrophoresis and sam-
ples sent for sequencing (using the Pfhrp2 internal for-
ward primer [21]) at Macrogen, Seoul, South Korea.
Plasma PFHRP2 was measured in freeze-thawed
EDTA plasma samples according to standard techni-
ques [25]. In brief a commercial sandwich ELISA kit
(Celisa, Cellabs, Sydney, Australia) was used according
to the manufacturer’s instructions with minor modifi-
cations and blinded to patient outcomes [8]. Pooled
reference plasma was derived from 20 subjects with
parasitaemia >200,000/μl and used to construct standard
curves.Figure 1 PfHRP2 levels and parasitaemias for samples examined. A: s
AQUAMAT centres; B: samples sequenced from Mozambique and TanzaniaStatistics
Comparisons of Pfhrp2 exon 2 length and repeat num-
ber were undertaken by the Mann–Whitney test in
GraphPad Prism.
Results
Assessment of possible deletion of Pfhrp2 or Pfhrp3
Plasma PFHRP2 was measured in 3,826 of the 5,426
children with pLDH-RDT-confirmed falciparum malaria
included in the AQUAMAT trial. The 80 samples asso-
ciated with lowest plasma PFHRP2 levels yielded 77
blood spots which were analysed using a semi-
quantitative approach for possible deletions in Pfhrp2 or
Pfhrp3 (Table 1, Figure 1a). These samples had a median
parasitaemia of 9,043/μl (compared to 79,397/μl for the
whole dataset). PCR for Pfhrp2 revealed bands of the
anticipated size in 70 cases; in seven cases (median para-
sitaemia 3,040/μl) no band could be obtained despite
repeated attempts. In all these Pfhrp2-negative cases, the
sample also had negative or very weak bands for Pfhrp3
as well as species identification, indicating that DNA
content of the sample was at or below the threshold of
detection. In an analogous manner, PCR for Pfhrp3 was
found to be positive in 67 samples, and was only nega-
tive (ten cases) when the other two reactions were nega-
tive or produced very dilute products.
Sequence polymorphism in Pfhrp2
In order to explore the relationship between Pfhrp2 se-
quence and plasma concentration, the aim was to obtainamples subjected to PCR for Pfhrp2 and Pfhrp3 across all relevant
(Teule site).
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zambique associated with extreme values of plasma
PFHRP2 (40 high, 40 low) but with relatively high per-
ipheral parasitaemias (greater than 10,000/μl) and hence
likely to produce reliable material for sequencing
(Figure 1b). Twenty-six clean PCR products suitable for
sequencing had already been obtained from these two
sites in the first phase of testing samples with low
PFHRP2 levels. An additional 62 (22 low PFHRP2, 40
high) samples therefore underwent DNA extraction and
Pfhrp2 PCR; all gave bands with no evidence of Pfhrp2
deletion. After sequencing, clear and complete exon 2
sequences were available in 34 samples from Mozam-
bique and 32 from Tanzania. Across these 66 samples,
37 patients had low PFHRP2 levels (median
(range) = 10.9 ng/ml (undetectable – 46.1)) while 29 had
high PFHRP2 levels (18,017 ng/ml (11,289–56,818)).
As expected from the gel electrophoresis results, and
consistent with previous findings [20-22], PCR products
were highly variable in length, as well as the numbers and
types of repeat (Figure 2a). For Mozambique the median
Pfhrp2 exon 2 PCR product length was 741 bp (range
627–816) and for Tanzania 759 (range 651–876) (p= 0.12;
Table 2). Of the repeat types described by Baker et al.,
types 2 (AHHAHHAAD) and 7 (AHHAAD) were the
most prominent (Figure 2b), constituting more than half
of each sequence; these were also the only repeat types
observed in all samples. All the other repeats documented
were fewer in number (no more than six of any repeat in
any sample). There was no significant difference in the
number of type 2, type 7 or any other repeat between Mo-
zambique and Tanzania (Figure 2b, Table 2) and the two
datasets were pooled to explore the possible association
between Pfhrp2 polymorphism and plasma levels.
Sequence length, number of type 2 repeats and num-
ber of type 7 repeats did not correlate with PFHRP2Figure 2 Pfhrp2 exon 2 length and repeat numbers according to coun
of type 2 and 7 repeats in each sample.plasma concentration when expressed as a continuous
variable (Figure 3a). There was also no significant differ-
ence in these sequence properties between low and high
categories of PFHRP2 (Figure 3b).
Discussion
PFHRP2 is released into the circulating plasma [8,26-
28] where it persists for several days [29]. Because of
the exponential rise in parasitaemia that occurs during
the development of P. falciparum in the blood, in
whole blood a large portion of PFHRP2 is located
within asexual parasites [27], and whole-blood PFHRP2
concentrations correlate, therefore, with peripheral
blood parasitaemia. By contrast, plasma PFHRP2 pro-
vides a summative picture of previous cycles of growth
that reflects sequestered parasite biomass rather than
circulating biomass [8]. Plasma PFHRP2 measurement
can therefore potentially be applied in the management
of severely ill patients in high transmission settings who
may be ill because of malaria or alternatively have an-
other severe illness, with malaria parasitaemia an inci-
dental finding [30]. Post-mortem reveals that 25% of
patients thought to have died of severe malaria have
other serious pathology [31]. Confident differentiation
of severe malaria from other pathologies where the
prevalence of malaria parasitaemia is high is very diffi-
cult [30]; observation of malarial retinopathy improves
the accuracy of diagnosis for cerebral malaria [32], but
requires skill and training and is rarely achievable in
practice outside centres of excellence. Since plasma
PFHRP2 derives from sequestered parasites that are
critical to the pathology of severe malaria, it has poten-
tial to differentiate ‘true’ severe malaria from alternative
illnesses in parasitaemic patients, as well as provide an
independent marker of prognostic significance in severe
malaria [8]. Plasma PFHRP2 levels were found to betry. A: frequency of each exon size (bin width of 20 bp); B: numbers
Table 2 Pfhrp2 exon 2 length and repeat polymorphism data by country
Population Mozambique Tanzania (Teule) Combined P value
Total number 34 32 66
Length: median (range) 741 (627–816) 759 (651–876) 751.5 (627–876) 0.12
Haplotypes 34 32 66
Repeats
Type 2 12 (10–17) 12 (8–16) 12 (8–17) 0.70
Type 7 7 (3–10) 8 (2–11) 7 (2–11) 0.22
The types and numbers of repeats for each sequence were examined using the repeat structure described by Baker et al. [21].
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pared to uncomplicated malaria in Indonesia [33] and
Thailand [8] although studies in Kenya [34] and Papua
New Guinea [35] did not find a significant difference.
Explanations for these apparently discrepant findings
include different classifications of disease severity as
well as differences in the intensity of transmission. A
particular problem in these studies, and in other studies
of severe malaria is the classification of children with
severe anaemia and low parasitaemia as having “severe
malaria”, many of whom have chronic anaemia and in-
cidental parasitaemia. These patients do not have large
numbers of sequestered parasites and so do not have
high plasma PFHRP2 concentrations.
The antibodies present in PFHRP2 RDT kits detect
the repetitive histidine-rich repeats encoded by exon 2
of Pfhrp2 (and Pfhrp3) [2,36]. This is a strength of
PFHRP2-based diagnosis, since the antigen sequence
appears many times within the protein and one protein
can be bound by several antibody molecules potentially
leading to amplification of signal and high assay sensitiv-
ity. However, the nature of the antigen detected opti-
mally by each RDT clearly differs between kits [2,36].Figure 3 Relationship between Pfhrp2 exon 2 length and plasma leveThe possibility that this might impair the accuracy of
RDTs was reflected for a time by a concern that certain
patterns of repeat polymorphism (relating to numbers of
type 2 and type 7 repeats) were associated with lower
levels of detection, based on a semi-quantitative analysis
of kit sensitivity [21]. Subsequent work has not sup-
ported this possibility and the performance of a range of
RDTs now appears unlikely to be confounded by se-
quence polymorphisms [22].
This study aimed to address the concern that quantifi-
cation of plasma PFHRP2 might be confounded by se-
quence polymorphism in terms of type and number of
histidine-containing repeats in PFHRP2. Among para-
sites from Mozambique and Tanzania, a diverse pattern
of repeat types was observed consistent with previous
studies from a wide range of African countries [20-22].
Within this variation, there was no relationship between
the number of repeats observed, or overall sequence
length, and plasma PFHRP2 level, mirroring the semi-
quantitative findings from studies examining rapid diag-
nostic tests [22]. These findings do not support the idea
that sequence polymorphism has a substantial influence
on ELISA-based PFHRP2 quantitation in Africanl. A: individual samples; B: categorized by PFHRP2 level.
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data that in Southeast Asian adult plasma PFHRP2 cor-
relates well with severity of disease [8,33], provide sup-
port for further work aimed at developing measurement
of plasma PFHRP2 as an aid to the diagnosis and the
management of severely ill African children [25].
Previous reports of field isolates with deletion of one
or both of these genes examined samples originating in
areas with generally low multiplicity of infection (MOI)
[17,18], or focused on samples from individuals with no
or few symptoms of malaria and hence likely to have
lower MOI [19]. In this survey of around 80 selected
parasite samples from patients admitted with a diagnosis
of severe malaria but with very low PFHRP2 plasma
levels across a number of African countries, there was
no evidence for deletion of either Pfhrp2 or Pfhrp3.
Multiplicity of infection was not measured, although it is
likely that a significant proportion of these samples con-
tained single infections, since around 10% contained in-
sufficient DNA to produce a PCR product in two
independent reactions. It is also worth noting that the
median asexual parasitaemia in this subgroup was about
9,000 parasites per μl, a figure similar to that associated
with false-negative RDTs in the recently published study
from Mali. The findings therefore provide a degree of re-
assurance regarding the prevalence of Pfhrp2 and Pfhrp3
deletion across the sites examined.
Conclusion
PFHRP2 sequence variation in parasites causing severe
malaria in Africa does not confound the quantification of
PFHRP2 antigen in plasma. This is a key element in the de-
velopment of plasma PFHRP2 concentration measurement
as a method for assessing African children who may have
severe falciparum malaria. The evidence supports the con-
cept that sequestered parasite biomass is the major cause
of variation of PFHRP2 concentration in patient samples.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TR and KP carried out the molecular biology. IH, JM-A, GM, RO, AT, MO, CK,
KM, EG, SG, LvS and HR were responsible for clinical data. KS and KC were
responsible for parasitological data. TR, IH, CIF, NW, ND, AD, MI and CW
participated in the design of the study. TR, KP, MI and CW were responsible
for data analysis and management. TR, MI and CW drafted the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
The study was supported by grants 076908 and 082541 from the Wellcome
Trust, and was coordinated as part of the Wellcome Trust Mahidol University
Oxford Tropical Medicine Research Programme funded by the Wellcome
Trust of Great Britain.
Author details
1Department of Clinical Tropical Medicine, Faculty of Tropical Medicine,
Mahidol University, Bangkok, Thailand. 2Mahidol-Oxford Tropical Medicine
Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok,Thailand. 3Centre for Clinical Vaccinology and Tropical Medicine, Churchill
Hospital, University of Oxford, Oxford, UK. 4Mbarara University of Science and
Technology and Epicentre Research Base, Mbarara, Uganda. 5National
Institute for Medical Research, Amani Centre, Tanga, Tanzania. 6MRC
laboratories, Banjul, The Gambia. 7Kinshasa School of Public Health, Kingasani
Research Centre, Kinshasa, DRC. 8Malaria Control Program, Ministry of Health,
Kigali, Rwanda. 9Kenya Medical Research Institute (KEMRI)–Wellcome Trust
Research Programme, Kilifi, Kenya. 10Hospital Central da Beira, Beira,
Mozambique. 11National Institute for Medical Research, Korogwe Research
Laboratory, Tanga, Tanzania. 12London School of Tropical Medicine and
Hygiene, London, UK. 13Department of Molecular Biotechnology and
Bioinformatics, Faculty of Science, Prince of Songkla University, Hat Yai,
Songkhla 90112, Thailand. 14Center for Genomics and Bioinformatics
Research, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla,
90112, Thailand. 15Menzies School of Health Research, Casuarina, NT,
Australia. 16Department of Molecular Tropical Medicine and Genetics, Faculty
of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Received: 23 May 2012 Accepted: 13 August 2012
Published: 16 August 2012References
1. Leech JH, Barnwell JW, Aikawa M, Miller LH, Howard RJ: Plasmodium
falciparum malaria: association of knobs on the surface of infected
erythrocytes with a histidine-rich protein and the erythrocyte skeleton.
J Cell Biol 1984, 98:1256–1264.
2. Lee N, Baker J, Andrews KT, Gatton ML, Bell D, Cheng Q, McCarthy J: Effect
of sequence variation in Plasmodium falciparum histidine- rich protein
2 on binding of specific monoclonal antibodies: Implications for rapid
diagnostic tests for malaria. J Clin Microbiol 2006, 44:2773–2778.
3. Otto TD, Wilinski D, Assefa S, Keane TM, Sarry LR, Bohme U, Lemieux J,
Barrell B, Pain A, Berriman M, Newbold C, Llinas M: New insights into the
blood-stage transcriptome of Plasmodium falciparum using RNA-Seq.
Mol Microbiol 2010, 76:12–24.
4. Marquart L, Butterworth A, McCarthy JS, Gatton ML: Modelling the
dynamics of Plasmodium falciparum histidine-rich protein 2 in human
malaria to better understand malaria rapid diagnostic test performance.
Malar J 2012, 11:74.
5. Rock EP, Marsh K, Saul AJ, Wellems TE, Taylor DW, Maloy WL, Howard RJ:
Comparative analysis of the Plasmodium falciparum histidine-rich
proteins HRP-I, HRP-II and HRP-III in malaria parasites of diverse origin.
Parasitology 1987, 95(Pt 2):209–227.
6. Shiff CJ, Premji Z, Minjas JN: The rapid manual ParaSight-F test. A new
diagnostic tool for Plasmodium falciparum infection. Trans R Soc Trop Med
Hyg 1993, 87:646–648.
7. Noedl H, Wernsdorfer WH, Miller RS, Wongsrichanalai C: Histidine-rich
protein II: a novel approach to malaria drug sensitivity testing. Antimicrob
Agents Chemother 2002, 46:1658–1664.
8. Dondorp AM, Desakorn V, Pongtavornpinyo W, Sahassananda D, Silamut K,
Chotivanich K, Newton PN, Pitisuttithum P, Smithyman AM, White NJ, Day
NP: Estimation of the total parasite biomass in acute falciparum malaria
from plasma PfHRP2. PLoS Med 2005, 2:e204.
9. Wellems TE, Howard RJ: Homologous genes encode two distinct
histidine-rich proteins in a cloned isolate of Plasmodium falciparum. Proc
Natl Acad Sci U S A 1986, 83:6065–6069.
10. Sullivan DJ Jr, Gluzman IY, Goldberg DE: Plasmodium hemozoin formation
mediated by histidine-rich proteins. Science 1996, 271:219–222.
11. Pologe LG, Ravetch JV: Large deletions result from breakage and healing
of P. falciparum chromosomes. Cell 1988, 55:869–874.
12. Kemp DJ, Thompson JK, Walliker D, Corcoran LM: Molecular karyotype of
Plasmodium falciparum: conserved linkage groups and expendable
histidine-rich protein genes. Proc Natl Acad Sci U S A 1987,
84(21):7672–7676.
13. Walliker D, Quakyi IA, Wellems TE, McCutchan TF, Szarfman A, London WT,
Corcoran LM, Burkot TR, Carter R: Genetic analysis of the human malaria
parasite Plasmodium falciparum. Science 1987, 236:1661–1666.
14. Wellems TE, Walliker D, Smith CL, do Rosario VE, Maloy WL, Howard RJ,
Carter R, McCutchan TF: A histidine-rich protein gene marks a linkage
group favored strongly in a genetic cross of Plasmodium falciparum.
Cell 1987, 49:633–642.
Ramutton et al. Malaria Journal 2012, 11:276 Page 7 of 7
http://www.malariajournal.com/content/11/1/27615. Walker-Jonah A, Dolan SA, Gwadz RW, Panton LJ, Wellems TE: An RFLP
map of the Plasmodium falciparum genome, recombination rates and
favored linkage groups in a genetic cross. Mol Biochem Parasitol 1992,
51:313–320.
16. Baker J, Gatton ML, Peters J, Ho MF, McCarthy JS, Cheng Q: Transcription
and expression of Plasmodium falciparum histidine-rich proteins in
different stages and strains: implications for rapid diagnostic tests. PLoS
One 2011, 6:e22593.
17. Gamboa D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW, Incardona
S, Perkins M, Bell D, McCarthy J, Cheng Q: A large proportion of P.
falciparum isolates in the Amazon region of Peru lack pfhrp2 and
pfhrp3: implications for malaria rapid diagnostic tests. PLoS One 2010,
5:e8091.
18. Houze S, Hubert V, Le Pessec G, Le Bras J, Clain J: Combined deletions of
pfhrp2 and pfhrp3 genes result in Plasmodium falciparum malaria
false-negative rapid diagnostic test. J Clin Microbiol 2011, 49:2694–2696.
19. Koita OA, Doumbo OK, Ouattara A, Tall LK, Konare A, Diakite M, Diallo M,
Sagara I, Masinde GL, Doumbo SN, Dolo A, Tounkara A, Traore I, Krogstad
DJ: False-negative rapid diagnostic tests for malaria and deletion of the
histidine-rich repeat region of the hrp2 Gene. AmJTrop Med Hyg 2012,
86:194–198.
20. Mariette N, Barnadas C, Bouchier C, Tichit M, Menard D: Country-wide
assessment of the genetic polymorphism in Plasmodium falciparum and
Plasmodium vivax antigens detected with rapid diagnostic tests for
malaria. Malar J 2008, 7:219.
21. Baker J, McCarthy J, Gatton M, Kyle DE, Belizario V, Luchavez J, Bell D, Cheng
Q: Genetic diversity of Plasmodium falciparum histidine-rich protein 2
(PfHRP2) and its effect on the performance of PfHRP2-based rapid
diagnostic tests. J Infect Dis 2005, 192:870–877.
22. Baker J, Ho MF, Pelecanos A, Gatton M, Chen N, Abdullah S, Albertini A,
Ariey F, Barnwell J, Bell D, Cunningham J, Djalle D, Echeverry DF, Gamboa D,
Hii J, Kyaw MP, Luchavez J, Membi C, Menard D, Murillo C, Nhem S, Ogutu
B, Onyor P, Oyibo W, Wang SQ, McCarthy J, Cheng Q: Global sequence
variation in the histidine-rich proteins 2 and 3 of Plasmodium falciparum:
implications for the performance of malaria rapid diagnostic tests. Malar
J 2010, 9:129.
23. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD,
Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T,
Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J,
Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A,
Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA,
Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D,
Wills B, Oneko M, Peto TE, von Seidlein L, Day NP, White NJ: Artesunate
versus quinine in the treatment of severe falciparum malaria in African
children (AQUAMAT): an open-label, randomised trial. Lancet 2010,
376:1647–1657.
24. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE,
Thaithong S, Brown KN: High sensitivity of detection of human malaria
parasites by the use of nested polymerase chain reaction. Mol Biochem
Parasitol 1993, 61:315–320.
25. Hendriksen ICE, Mwanga-Amumpaire J, von Seidlein L, Mtove G, White LJ,
Olaosebikan R, Lee SJ, Tshefu AK, Woodrow CJ, Amos B, Karema C, Saiwaew
S, Maitland K, Gomes E, Pan-Ngum W, Gesase S, Silamut K, Reyburn H,
Joseph S, Chotivanich K, Fanello CI, Day NPJ, White NJ, Dondorp AM:
Diagnosing severe falciparum malaria in parasitaemic African children; a
prospective evaluation of plasma PfHRP2 measurement. PLoS Med 2012,
9:e1001297.
26. Howard RJ, Uni S, Aikawa M, Aley SB, Leech JH, Lew AM, Wellems TE, Rener
J, Taylor DW: Secretion of a malarial histidine-rich protein (Pf HRP II) from
Plasmodium falciparum-infected erythrocytes. J Cell Biol 1986,
103:1269–1277.
27. Desakorn V, Dondorp AM, Silamut K, Pongtavornpinyo W, Sahassananda D,
Chotivanich K, Pitisuttithum P, Smithyman AM, Day NP, White NJ:
Stage-dependent production and release of histidine-rich protein 2 by
Plasmodium falciparum. Trans R Soc Trop Med Hyg 2005,
99:517–524.
28. Desakorn V, Silamut K, Angus B, Sahassananda D, Chotivanich K,
Suntharasamai P, Simpson J, White NJ: Semi-quantitative measurement of
Plasmodium falciparum antigen PfHRP2 in blood and plasma. Trans R Soc
Trop Med Hyg 1997, 91:479–483.29. Biswas S, Tomar D, Rao DN: Investigation of the kinetics of histidine-rich
protein 2 and of the antibody responses to this antigen, in a group of
malaria patients from India. Ann Trop Med Parasitol 2005, 99:553–562.
30. Bejon P, Berkley JA, Mwangi T, Ogada E, Mwangi I, Maitland K, Williams T,
Scott JA, English M, Lowe BS, Peshu N, Newton CR, Marsh K: Defining
childhood severe falciparum malaria for intervention studies. PLoS Med
2007, 4:e251.
31. Taylor TE, Fu WJ, Carr RA, Whitten RO, Mueller JS, Fosiko NG, Lewallen S,
Liomba NG, Molyneux ME: Differentiating the pathologies of cerebral
malaria by postmortem parasite counts. Nat Med 2004, 10:143–145.
32. Beare NA, Taylor TE, Harding SP, Lewallen S, Molyneux ME: Malarial
retinopathy: a newly established diagnostic sign in severe malaria.
AmJTrop Med Hyg 2006, 75:790–797.
33. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, Piera K, Price RN,
Duffull SB, Celermajer DS, Anstey NM: Angiopoietin-2 is associated with
decreased endothelial nitric oxide and poor clinical outcome in severe
falciparum malaria. Proc Natl Acad Sci U S A 2008, 105:17097–17102.
34. Ochola LB, Marsh K, Lowe B, Gal S, Pluschke G, Smith T: Estimation of the
sequestered parasite load in severe malaria patients using both host
and parasite markers. Parasitology 2005, 131(Pt 4):449–458.
35. Manning L, Laman M, Stanisic D, Rosanas-Urgell A, Bona C, Teine D, Siba P,
Mueller I, Davis TM: Plasma Plasmodium falciparum histidine-rich protein-
2 concentrations do not reflect severity of malaria in Papua new
guinean children. Clin Infect Dis 2011, 52:440–446.
36. Lee N, Gatton ML, Pelecanos A, Bubb M, Gonzalez I, Bell D, Cheng Q,
McCarthy JS: Identification of optimal epitopes for Plasmodium
falciparum Rapid Diagnostic Tests that target histidine-rich proteins
2 and 3. J Clin Microbiol 2012, 50:1397–1405.
doi:10.1186/1475-2875-11-276
Cite this article as: Ramutton et al.: Sequence variation does not
confound the measurement of plasma PfHRP2 concentration in African
children presenting with severe malaria. Malaria Journal 2012 11:276.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
